{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:56:12Z","timestamp":1792788972079,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["974\/19"],"award-info":[{"award-number":["974\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Krieger Foundation","award":["974\/19"],"award-info":[{"award-number":["974\/19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Mesothelioma, an aggressive cancer with a poor prognosis, is linked to asbestos exposure. However, carbon nanotubes found in materials we are exposed to daily can cause mesothelioma cancer. Cancer cells reprogram their metabolism to support increased biosynthetic and energy demands required for their growth and motility. Here, we examined the effects of silencing the expression of the voltage-dependent anion channel 1 (VDAC1), controlling the metabolic and energetic crosstalk between mitochondria and the rest of the cell. We demonstrate that VDAC1 is overexpressed in mesothelioma patients; its levels increase with disease stage and are associated with low survival rates. Silencing VDAC1 expression using a specific siRNA identifying both mouse and human VDAC1 (si-m\/hVDAC1-B) inhibits cell proliferation of mesothelioma cancer cells. Treatment of xenografts of human-derived H226 cells or mouse-derived AB1 cells with si-m\/hVDAC1-B inhibited tumor growth and caused metabolism reprogramming, as reflected in the decreased expression of metabolism-related proteins, including glycolytic and tricarboxylic acid (-)cycle enzymes and the ATP-synthesizing enzyme. In addition, tumors depleted of VDAC1 showed altered microenvironments and inflammation, both associated with cancer progression. Finally, tumor VDAC1 silencing also eliminated cancer stem cells and induced cell differentiation to normal-like cells. The results show that silencing VDAC1 expression leads to reprogrammed metabolism and to multiple effects from tumor growth inhibition to modulation of the tumor microenvironment and inflammation, inducing differentiation of malignant cells. Thus, silencing VDAC1 is a potential therapeutic approach to treating mesothelioma.<\/jats:p>","DOI":"10.3390\/biom12070895","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T22:31:14Z","timestamp":1656369074000},"page":"895","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-9453","authenticated-orcid":false,"given":"Swaroop Kumar","family":"Pandey","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"},{"name":"The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renen","family":"Machlof-Cohen","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manikandan","family":"Santhanam","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"},{"name":"The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shteinfer-Kuzmine","sequence":"additional","affiliation":[{"name":"The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-4340","authenticated-orcid":false,"given":"Varda","family":"Shoshan-Barmatz","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"},{"name":"The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1179\/2049396712Y.0000000016","article-title":"Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003\u20132008","volume":"19","author":"Henley","year":"2013","journal-title":"Int. J. Occup. Environ. Health"},{"key":"ref_2","first-page":"396","article-title":"Primary Malignant Pericardial Mesothelioma. Presenting as Pericardial Constriction","volume":"14","author":"Kainuma","year":"2008","journal-title":"Ann. Thorac Cardiovas."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1539\/joh.16-2002-ST","article-title":"The global health dimensions of asbestos and asbestos-related diseases","volume":"58","author":"Ramazzini","year":"2016","journal-title":"J. Occup. Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.ajpath.2011.02.040","article-title":"Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura","volume":"178","author":"Murphy","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/oem.2007.032847","article-title":"Cancer risk after cessation of asbestos exposure: A cohort study of Italian asbestos cement workers","volume":"65","author":"Magnani","year":"2008","journal-title":"Occup. Environ. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Alfaleh, M.A., Howard, C.B., Sedliarou, I., Jones, M.L., Gudhka, R., Vanegas, N., Weiss, J., Suurbach, J.H., de Bakker, C.J., and Milne, M.R. (2017). Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186137"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10552-009-9357-4","article-title":"Ionizing radiation: A risk factor for mesothelioma","volume":"20","author":"Goodman","year":"2009","journal-title":"Cancer Cause Control."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canep.2014.02.014","article-title":"Familial malignant mesothelioma: A population-based study in central Italy (1980\u20132012)","volume":"38","author":"Ascoli","year":"2014","journal-title":"Cancer Epidemiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant Mesothelioma and Its Non-Asbestos Causes","volume":"142","author":"Attanoos","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: Recent highlights","volume":"5","author":"Carbone","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1016\/j.cub.2017.09.007","article-title":"Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a\/Arf)","volume":"27","author":"Chernova","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12989-014-0059-z","article-title":"The carcinogenic effect of various multi-walled carbon nanotubes (MWCNTs) after intraperitoneal injection in rats","volume":"11","author":"Rittinghausen","year":"2014","journal-title":"Part Fibre Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.addr.2013.07.014","article-title":"Pulmonary toxicity of carbon nanotubes and asbestos\u2014similarities and differences","volume":"65","author":"Donaldson","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2010.06.015","article-title":"Biopersistent fiber-induced inflammation and carcinogenesis: Lessons learned from asbestos toward safety of fibrous nanomaterials","volume":"502","author":"Nagai","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: A retrospective study","volume":"10","author":"Monica","year":"2015","journal-title":"J. Thorac Oncol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/imt.16.4","article-title":"Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy","volume":"8","author":"Stashwick","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt\/PI3K\/NF-kappaB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/srep01870","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1073\/pnas.0604008103","article-title":"TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis","volume":"103","author":"Yang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14737140.2016.1244008","article-title":"Targeting the vasculature: Anti-angiogenic agents for malignant mesothelioma","volume":"16","author":"Chia","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_26","first-page":"476","article-title":"Histone Deacetylase Inhibitors as Potential Therapeutic Agents for the Treatment of Malignant Mesothelioma","volume":"13","author":"Katafygiotis","year":"2013","journal-title":"Anti-Cancer Agent Me"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33844","DOI":"10.18632\/oncotarget.26117","article-title":"The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model","volume":"9","author":"Mizukami","year":"2018","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.mam.2010.03.002","article-title":"VDAC, a multi-functional mitochondrial protein regulating cell life and death","volume":"31","author":"Zweckstetter","year":"2010","journal-title":"Mol. Aspects Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.bbamem.2014.10.040","article-title":"The mitochondrial voltage-dependent anion channel 1 in tumor cells","volume":"1848","author":"Admoni","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1038\/mtna.2014.9","article-title":"Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo","volume":"3","author":"Arif","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2147\/IJN.S200253","article-title":"Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach","volume":"14","author":"Dana","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fonc.2017.00154","article-title":"Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics","volume":"7","author":"Krelin","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/iub.2407","article-title":"Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer","volume":"73","author":"Verma","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1073\/pnas.0600103103","article-title":"The expression level of the voltage-dependent anion channel controls life and death of the cell","volume":"103","author":"Sivan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4161\/cbt.9.12.11879","article-title":"Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo","volume":"9","author":"Koren","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Amsalem, Z., Arif, T., Shteinfer-Kuzmine, A., Chalifa-Caspi, V., and Shoshan-Barmatz, V. (2020). The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link. Cancers, 12.","DOI":"10.3390\/cancers12041031"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/now297","article-title":"VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties","volume":"19","author":"Arif","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Arif, T., Paul, A., Krelin, Y., Shteinfer-Kuzmine, A., and Shoshan-Barmatz, V. (2018). Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States. Cancers, 10.","DOI":"10.3390\/cancers10120499"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1124\/jpet.112.192153","article-title":"Warburg revisited: Regulation of mitochondrial metabolism by voltage-dependent anion channels in cancer cells","volume":"342","author":"Maldonado","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Varghese, F., Bukhari, A.B., Malhotra, R., and De, A. (2014). IHC Profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096801"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cns.13044","article-title":"Degeneration of white matter and gray matter revealed by diffusion tensor imaging and pathological mechanism after spinal cord injury in canine","volume":"25","author":"Liu","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: An update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcancer.2014.07.001","article-title":"Cancer stem cells, cancer cell plasticity and radiation therapy","volume":"31","author":"Vlashi","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/jcb.22350","article-title":"Cancer stem cells: Cell culture, markers, and targets for new therapies","volume":"108","author":"Gilbert","year":"2009","journal-title":"J. Cell Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"Laurenti","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/stem.1352","article-title":"Concise Review: The Sox2-Oct4 Connection: Critical Players in a Much Larger Interdependent Network Integrated at Multiple Levels","volume":"31","author":"Rizzino","year":"2013","journal-title":"Stem Cells"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/d41586-018-05867-7","article-title":"Gene-silencing technology gets first drug approval after 20-year wait","volume":"560","author":"Ledford","year":"2018","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.biomaterials.2011.09.061","article-title":"Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors","volume":"33","author":"Zhou","year":"2012","journal-title":"Biomaterials"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic Targeting of the Tumor Microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/ajcp\/110.3.374","article-title":"CD31 immunoreactivity in carcinomas and mesotheliomas","volume":"110","author":"Frierson","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41419-019-1883-8","article-title":"The role of pyroptosis in cancer: Pro-cancer or pro-\"host\"?","volume":"10","author":"Xia","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/dc.20938","article-title":"Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis","volume":"37","author":"Cakir","year":"2009","journal-title":"Diagn. Cytopathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"102413","DOI":"10.1016\/j.isci.2021.102413","article-title":"Cytokeratin 5 determines maturation of the mammary myoepithelium","volume":"24","author":"Deckwirth","year":"2021","journal-title":"iScience"},{"key":"ref_58","first-page":"197","article-title":"Establishment of three novel human malignant pleural mesothelioma cell lines: Morphological and cytogenetical studies and EGFR mutation status","volume":"28","author":"Kobayashi","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/modpathol.3800534","article-title":"Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity","volume":"19","author":"Yaziji","year":"2006","journal-title":"Mod. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/oli.2008.0164","article-title":"Chemical modification of siRNAs for in vivo use","volume":"18","author":"Behlke","year":"2008","journal-title":"Oligonucleotides"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: Fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1517\/14728222.9.6.1217","article-title":"Exploring the tumour environment: Cancer-associated fibroblasts as targets in cancer therapy","volume":"9","author":"Micke","year":"2005","journal-title":"Expert Opin. Ther. Tar."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcancer.2004.06.006","article-title":"Inflammation as a tumor promoter in cancer induction","volume":"14","author":"Philip","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.2224","article-title":"Inflammasomes in carcinogenesis and anticancer immune responses","volume":"13","author":"Zitvogel","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12929-021-00724-8","article-title":"NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer","volume":"28","author":"Faria","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Westbom, C., Thompson, J.K., Leggett, A., MacPherson, M., Beuschel, S., Pass, H., Vacek, P., and Shukla, A. (2015). Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145404"},{"key":"ref_71","first-page":"1227","article-title":"Loss of caspase-1 and caspase-3 protein expression in human prostate cancer","volume":"61","author":"Winter","year":"2001","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cas.12817","article-title":"Therapeutic strategies targeting cancer stem cells","volume":"107","author":"Yoshida","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.yexmp.2015.02.002","article-title":"Cancer stem cell: Fundamental experimental pathological concepts and updates","volume":"98","author":"Islam","year":"2015","journal-title":"Exp. Mol. Pathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1074\/jbc.M111.268920","article-title":"Structure-based analysis of VDAC1 protein: Defining oligomer contact sites","volume":"287","author":"Geula","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtn.2019.05.003","article-title":"Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells","volume":"17","author":"Arif","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Arif, T., Stern, O., Pittala, S., Chalifa-Caspi, V., and Shoshan-Barmatz, V. (2019). Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept. Cells, 8.","DOI":"10.3390\/cells8111330"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/7\/895\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:56Z","timestamp":1760139536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/12\/7\/895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biom12070895"],"URL":"https:\/\/doi.org\/10.3390\/biom12070895","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]}}}